Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profile of [14C]-Pracinostat in Healthy Males
NCT03495934Phase 1Completed
- Sponsor
- Helsinn
- Start
- Feb 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pracinostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Helsinn. Primary endpoints: Mass balance recovery up to 12 days, Area Under the Curve up to 8 days and 4 more. Started Feb 2018; status: completed.
02
Drugs
pracinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03495934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495934.